Growth Metrics

Gilead Sciences (GILD) Gross Margin (2009 - 2026)

Gilead Sciences posted quarterly Gross Margin of 79.24% for Q1 2026, up 234.0% year-on-year from 23.72% in Q1 2025, and little changed on a QoQ basis from 79.51% in Q4 2025.

Gilead Sciences (GILD) has 18 years of Gross Margin data on file, last reported at 79.24% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin rose 234.0% year-over-year to 79.24%; the trailing twelve-month figure through Mar 2026 stood at 79.35% (up 107.0% YoY), and the FY2025 full-year result was 78.83%, up 57.0% from the prior year.
  • Gross Margin for Q1 2026 stood at 79.24%, roughly flat from 79.51% in the prior quarter.
  • Across five years, Gross Margin topped out at 81.11% in Q4 2022 and bottomed at 70.62% in Q4 2023.
  • The 5-year median for Gross Margin is 78.39% (2022), against an average of 78.13%.
  • The widest annual swing landed in 2022, when Gross Margin jumped 1737 bps; it then slumped 1049 bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 81.11% in 2022, then decreased by 13 bps to 70.62% in 2023, then rose by 12 bps to 79.11% in 2024, then increased by 1 bps to 79.51% in 2025, then slipped by 0 bps to 79.24% in 2026.
  • The last three Gross Margin figures came in at 79.24% (Q1 2026), 79.51% (Q4 2025), and 79.8% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 81.93%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 66.31%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 71.88%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 74.24%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 68.16%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 79.24%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -51.69%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 70.22%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 79.24%
Dec 31, 2025 79.51%
Sep 30, 2025 79.80%
Jun 30, 2025 78.81%
Mar 31, 2025 76.90%
Dec 31, 2024 79.11%
Sep 30, 2024 79.14%
Jun 30, 2024 77.80%
Mar 31, 2024 76.79%
Dec 31, 2023 70.62%
Sep 30, 2023 77.80%
Jun 30, 2023 78.15%
Mar 31, 2023 77.94%
Dec 31, 2022 81.11%
Sep 30, 2022 80.19%
Jun 30, 2022 76.96%
Mar 31, 2022 78.39%
Dec 31, 2021 63.74%
Sep 30, 2021 83.52%
Jun 30, 2021 77.64%
Mar 31, 2021 78.81%
Dec 31, 2020 81.16%
Sep 30, 2020 82.65%
Jun 30, 2020 79.31%
Mar 31, 2020 82.53%
Dec 31, 2019 71.37%
Sep 30, 2019 81.53%
Jun 30, 2019 82.41%
Mar 31, 2019 81.88%
Dec 31, 2018 72.91%
Sep 30, 2018 80.59%
Jun 30, 2018 78.82%
Mar 31, 2018 80.33%
Dec 31, 2017 78.89%
Sep 30, 2017 84.15%
Jun 30, 2017 84.23%
Mar 31, 2017 85.29%
Dec 31, 2016 85.31%
Sep 30, 2016 84.95%
Jun 30, 2016 88.89%
Mar 31, 2016 84.69%
Dec 31, 2015 87.51%
Sep 30, 2015 87.17%
Jun 30, 2015 87.89%
Mar 31, 2015 88.39%
Dec 31, 2014 85.47%
Sep 30, 2014 83.66%
Jun 30, 2014 85.85%
Mar 31, 2014 83.74%
Dec 31, 2013 72.50%
Sep 30, 2013 72.86%
Jun 30, 2013 71.29%
Mar 31, 2013 69.48%
Dec 31, 2012 73.90%
Sep 30, 2012 72.56%
Jun 30, 2012 70.84%
Mar 31, 2012 71.30%
Dec 31, 2011 73.44%
Sep 30, 2011 72.30%
Jun 30, 2011 70.45%
Mar 31, 2011 72.14%
Dec 31, 2010 75.17%
Sep 30, 2010 75.35%
Jun 30, 2010 76.36%
Mar 31, 2010 78.88%
Dec 31, 2009 76.71%
Sep 30, 2009 77.26%
Jun 30, 2009 76.75%
Mar 31, 2009 78.48%